anonymous
Guest
anonymous
Guest
They talk so much about specialty sales just wondering if that only means STMs will remain.
Yes. There will be TM’s selling Eliquis and there will be TM’s in the womens health portfolio.won’t we need TMs in order to fulfill the contact with BMS?
Ciloguard contract gone at the end of the year. Rumor has it that BMS is also pulling out due to Pfizers emphasis on call centers and not on live reps in the field.
Boy are you living in fantasy land.Haha!If anything Pfizer would buy Eliquis from BMS..
Keep telling yourself that. 1 product to sell. Pfizer will not hold an entire team of this size for a product that sells itself. BMS will find a way out and LOE is not that far away. We became an absolute joke to BMS in our time out of the field. This thing is coming to a close.Eliquis isn’t going anywhere, and Pfizer will do whatever they need to do to meet the terms of the contract, it is billions of dollars per year at stake.
unless we have some great IV antibiotic that’s administered in the hospital, we haven’t needed a hospital force for decades.No need for the hospital team
They were supposed to pull through Eliquis in the hospitals, but Xalrelto got the business.No need for the hospital team
Only TMs left are T2 and vaccines. I imagine both will have deep cuts.They talk so much about specialty sales just wondering if that only means STMs will remain.
Where do you work?????They were supposed to pull through Eliquis in the hospitals, but Xalrelto got the business.